Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 143,199 shares at $0.32 ($45K) on 2026-07-06, disclosed to the SEC on 2026-07-08.
Scheduled sale ($45k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.32 | 35,770 | $11K | 25.6% |
| 2 | $0.31 | 107,429 | $33K | 74.4% |
| Total | $0.31 avg | 143,199 | $45K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |
| HOWL | SELL | 2026-05-29 | $66K | — | Filing → |